Wall Street brokerages forecast that Nektar Therapeutics (NASDAQ:NKTR) will post ($0.71) earnings per share for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Nektar Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.62) and the lowest estimate coming in at ($0.82). Nektar Therapeutics reported earnings per share of ($0.60) during the same quarter last year, which suggests a negative year-over-year growth rate of 18.3%. The company is scheduled to issue its next earnings report on Thursday, May 9th.
According to Zacks, analysts expect that Nektar Therapeutics will report full-year earnings of ($3.02) per share for the current financial year, with EPS estimates ranging from ($3.28) to ($2.49). For the next financial year, analysts forecast that the company will report earnings of ($2.74) per share, with EPS estimates ranging from ($3.93) to ($1.32). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that follow Nektar Therapeutics.
Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.13. Nektar Therapeutics had a net margin of 57.09% and a return on equity of 50.22%. During the same quarter last year, the firm earned ($0.21) EPS.
In related news, SVP Jillian B. Thomsen sold 16,119 shares of the business’s stock in a transaction on Monday, February 4th. The shares were sold at an average price of $42.16, for a total value of $679,577.04. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO John Nicholson sold 63,000 shares of the business’s stock in a transaction on Monday, January 28th. The shares were sold at an average price of $42.82, for a total transaction of $2,697,660.00. Following the completion of the transaction, the chief operating officer now owns 237,477 shares in the company, valued at approximately $10,168,765.14. The disclosure for this sale can be found here. In the last 90 days, insiders sold 241,824 shares of company stock worth $10,249,993. 4.31% of the stock is owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. Norges Bank bought a new stake in Nektar Therapeutics in the fourth quarter valued at $63,723,000. Burleson & Company LLC increased its stake in Nektar Therapeutics by 7.6% in the fourth quarter. Burleson & Company LLC now owns 7,098 shares of the biopharmaceutical company’s stock valued at $286,000 after purchasing an additional 500 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Nektar Therapeutics by 82.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 408,526 shares of the biopharmaceutical company’s stock valued at $13,433,000 after purchasing an additional 184,055 shares in the last quarter. FMR LLC increased its stake in Nektar Therapeutics by 8.5% in the fourth quarter. FMR LLC now owns 25,961,520 shares of the biopharmaceutical company’s stock valued at $853,355,000 after purchasing an additional 2,041,954 shares in the last quarter. Finally, Kentucky Retirement Systems bought a new stake in Nektar Therapeutics in the fourth quarter valued at $247,000. Institutional investors and hedge funds own 93.35% of the company’s stock.
Shares of NASDAQ:NKTR opened at $33.48 on Tuesday. The firm has a market cap of $5.99 billion, a PE ratio of 8.86 and a beta of 3.09. The company has a current ratio of 17.53, a quick ratio of 17.39 and a debt-to-equity ratio of 0.14. Nektar Therapeutics has a 52 week low of $29.22 and a 52 week high of $108.23.
About Nektar Therapeutics
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
Recommended Story: Is it Safe to Invest in Commodities?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.